Developments in personalized management show promise for improving dry eye treatment, indicating significant progress.
The evolving understanding of DED supports a shift toward mechanism-based, personalized management that addresses inflammation, tear film instability, neurosensory dysfunction, and glandular insufficiency. Integrating targeted therapies, device-based interventions, and regenerative approaches with improved diagnostics may enable more predictable, proactive care. Rigorous research is still needed to optimize treatment selection and sequencing.
No takes yet. Share an insight, caveat, or question.
Rossi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: